Clinical Trial Update: Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments [Phase 1, Phase 2]

View source ↗

Summary

Rollover study update for participants who previously received Opnurasib, either as a single agent or in combination, continuing in Phase 1/Phase 2 trials for K…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kras G12c-mutated Solid Tumors
• Or Metastatic Non-small Cell Lung Cancer

Drugs mentioned

• Opnurasib (opnurasib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING